Dr. Praneeth Kuninty

Position: Post Doctoral Researcher
In the Lab since: 2013
Research Interests: - Nanomedicine
                                  - Tumor-associated macrophages/fibroblasts
                                  - Integrins
                                  - miRNAs
                                  - Peptides

My Personal Goal: "Investigating novel therapeutics for the targeted modulation of the tumor microenvironment"  

Contact: p.r.kuninty@utwente.nl
Location: ZH 255

About me

Originally I am from Adilabad, India. In 2010, I have obtained my Bachelor of Pharmacy from J.S.S College of Pharmacy, Mysore. In 2013, I graduated from the University of Groningen, The Netherland, with a Master in Medical Pharmaceutical Sciences. My main Master research project was about the “Characterization of Inulin Nanocrystals”. Later I did his second master project on the “SAINT-Lipid Polycation particles, a novel carrier for an improved delivery of siRNA to activated primary endothelial cells”, where I developed a particular interest in targeted nanotherapeutics. In July 2013, I joined the Targeted Therapeutics group of Jai Prakash as a Ph.D. student. The main focus of my PhD thesis was the pancreatic tumor stroma, where I investigated novel therapeutics for the treatment of pancreatic ductal adenocarcinoma. In Nov 2017, I have obtained my Ph.D. on the topic “Novel Targeting Strategies against Pancreatic Stellate Cells to treat Pancreatic Cancer”. Thereafter, in the same group, I started working as a postdoctoral researcher on pancreatic and breast tumor microenvironment.

Honors & Awards

- Won best poster award at the 1st Pancreas Spring Meeting, Gottingen, 11-12 May 2017 on targeting integrin alpha5 as a novel strategy to treat a pancreatic tumor in vivo.


- “Laboratory Animal Science” course and received article 9 license to perform experiments on animals from the University of Groningen, the Netherlands.


Schnittert J., Heinrich MA., Kuninty PR., Storm G., Prakash J.
''Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer''
Accepted by Cancer Letters.


Schnittert J., Kuninty PR., Bystry TF., Brock R., Storm G., Prakash J.
''Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells''
Nanomedicine (Lond). 2017 May 19. doi: 10.2217/nnm-2017-0054.
PMID: 28524768

Strell C., Norberg KJ., Mezheyeuski A., Schnittert J., Kuninty PR., Moro CF., Paulsson J., Schultz NA., Calatayud D., Löhr JM., Frings O., Verbeke CS., Heuchel RL., Prakash J., Johansen JS., Östman A.
''Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC''
Br J Cancer. 2017 Jun 27;117(1):65-77. doi: 10.1038/bjc.2017.140. Epub 2017 May 18.
PMID: 28524160


Kuninty PR., Bojmar L., Tjomsland V., Larsson M., Storm G., Östman A., Sandström P., Prakash J.
''MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor''
Oncotarget. 2016 Mar 29;7(13):16396-408. doi: 10.18632/oncotarget.7651.
PMID: 26918939

Kuninty PR., Schnittert J., Storm G., Prakash J.
''MicroRNA Targeting to Modulate Tumor Microenvironment.''
Front Oncol. 2016 Jan 19;6:3. doi: 10.3389/fonc.2016.00003. eCollection 2016. Review.
PMID: 26835418


Kowalski PS., Kuninty PR., Bijlsma KT., Stuart MC., Leus NG., Ruiters MH., Molema G., Kamps JA.
"SAINT-liposome-polycation particles, a new carrier for improved delivery of siRNAs to inflamed endothelial cells"
Eur J Pharm Biopharm. 2015 Jan;89:40-7. doi: 10.1016/j.ejpb.2014.11.015. Epub 2014 Nov 25.